Gilead Sciences (NASDAQ:GILD – Free Report) had its price target raised by Oppenheimer from $115.00 to $132.00 in a report ...

Gilead Sciences' Q4 2024 results, driven by HIV drug demand and Trodelvy growth, make it a compelling choice for long-term ...

Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor ...

Stock analysts at Zacks Research reduced their Q3 2026 earnings per share estimates for shares of Gilead Sciences in a research report issued on Tuesday, February 25th. Zacks Research analyst E. Bagri ...

Learn more about whether Gilead Sciences, Inc. or Insmed Incorporated is a better investment based on AAII's A+ Investor ...

Detailed price information for Gilead Sciences Inc (GILD-Q) from The Globe and Mail including charting and trades.

The EU drugs regulator says Gilead Sciences’ antiviral drug remdesivir should be made available for people seriously ill with COVID-19, despite limited data on its efficacy. The EMA’s human ...

Gilead Sciences Inc. GILD stock surged to a new ... including Veklury sales of $1.4 billion, which is its COVID-19 treatment. 2) Gilead’s HIV, Oncology, and Liver Disease Franchise Continues ...

Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the fourth quarter and full year 2024.

Good afternoon, everyone, and welcome to Gilead's Fourth Quarter and Full ... primarily due to lower rates of COVID-19 hospitalizations, and typical of the quarterly variability we've seen with ...

The major backer of the lenacapavir roll-out is assuring nervous researchers that they will keep their part of funding ...

The pharma industry is delivering game-changing therapies with favorable regulatory support. Amid this backdrop, investors ...